Trump’s early tough talk on drug pricing is now a pro-industry, anti-regulation GOP dreamscape By Bryn Gay Unaffordable drug prices were a hot-button topic on the 2016 U.S. presidential campaign trail and remain a significant source of frustration among Democrats…
Mobilizing to defend biomedical research investments and scientific integrity as essential for public health, safety, and well-being By Kenyon Farrow and Mike Frick One of the more memorable moments of resistance to the Trump administration’s and GOP-controlled Congress’ plan to…
Maintaining and expanding the accomplishments of the past depend on a fight for their survival and growth—now more than ever By Mark Harrington Today’s political situation with respect to the struggle to end HIV/AIDS, to treat all of those infected,…
We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color. By Jeremiah Johnson In February 2016, the CDC issued a new report with a…
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South By Bryn Gay We can now cure the hepatitis C virus (HCV) with a coformulation of drugs that yields sustained virologic responses for all…
We can’t end the viral hepatitis epidemics unless we end the war on drug users By Annette Gaudino “Unidentified Filipino male. Unidentified Filipino male. Unidentified Filipino female. Unidentified Filipino male…” It takes a long time to read 1,900 names, long…
4A case for a racial justice agenda in treatment and research By Kenyon Farrow The Tuskegee Syphilis study remains a primary citation in both the scientific literature and popular conversations to explain the reluctance of African Americans to engage with…
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…
Pharma’s Obligations Under the Right to Science By Erica Lessem and Brian Citro Benefitting from scientific progress is a human right, but who’s responsible for ensuring that this right is upheld? As Mike Frick clearly lays out in “Science and…